Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Meet Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR) criteria for bipolar I or II disorder without psychotic features based on the Mini International Neuropsychiatric Interview (MINI), with a current depressive episode of at least 4 weeks and not exceeding 12 months.
Have a minimum score of 20 on the 17-item Hamilton Depression Rating Scale (HAMD-17).
Have a minimum score of 2 on Item 1 of the HAMD-17 at screening.
You may not be if
Positive urine drug screen (UDS) result at screening.
Treated with any investigational drug within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the first dose of study drug, is currently enrolled in another clinical study, or was previously enrolled in this study.
Current use of any antipsychotic, antidepressant, anticonvulsant, mood stabilizer, herb, or over-the-counter medication with psychoactive potential within 1 week or 5 half-lives of the medication (whichever is longer).
Prior exposure to ABBV-932 within 90 days prior to baseline.
Clareo Health | Study of Oral ABBV-932 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Bipolar I or II Disorder
